Pfizer Orgovyx (relugolix by Year

Name: Pfizer Orgovyx (relugolix by Year (PFE)
Creator: Pfizer

Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) ($M)

Quarterly Annual

Pfizer Orgovyx (relugolix: $421M in FY2025, up 109.5% from a year earlier.

Latest, FY2025

421

Period ended Dec 31, 2025

Change on a year earlier

+109.5%

201 in FY2024

History

3 years

Since FY2023

Sources

Documents cited below

Where the FY2025 figure comes from

“|| Orgovyx (i) | 421 | 201 | * | * | 421 | 201 | * | — | — | — | —”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	421	+109.5%	Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024	Dec 31, 2024	201	+67.5%	Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023	Dec 31, 2023	120	–	Form 10-K (filed 2026-02-26) ↗

Breakdown

What makes up orgovyx (relugolix

Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. revenues ($M)421 · FY2025

Cite this data

StockData. (2026). Pfizer Orgovyx (relugolix ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/orgovyx-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.